Tiotropium
- TRADE NAMES: Spiriva (Boehringer Ingelheim); Stiolto Respimat (Boehringer Ingelheim)
- INDICATIONS: Bronchospasm (associated with COPD)
- CLASS: Anticholinergic, Muscarinic antagonist
- HALF-LIFE: 5–6 days
Acetylcholinesterase inhibitors, Anticholinergics, Antihistamines, Botulinum Toxin (A & B), Cannabinoids, Conivaptan, Disopyramide, Domperidone, Haloperidol, Ketoconazole, Levodopa, MAO inhibitors, Memantine, Metoclopramide, Nefopam, Parasympathomimetics, PEG-Interferon, Phenothiazines, Potassium chloride, Pramlintide, Secretin, Sublingual nitrates, Tricyclic antidepressants
PREGNANCY CATEGORY: C
Stiolto Respimat is tiotropium and olodaterol.
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of tiotropium in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 09/19/2018
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
